An analysis of the effect of Oxaliplatin in inducing immunogenetic celldeath and improving the efficacy of checkpoint inhibitor on SGC-7901
DOI:
https://doi.org/10.61173/daja4419Keywords:
SGC-7901, Oxaliplatin, PD-L1, aPD-L1, checkpoint (inhibitor)Abstract
Previous studies demonstrated Oxaliplatin, a derivative of Cisplatin, to have anti-cancer properties in a Lewis Lung
Carcinoma (LLC). It can induce immunogenic cell death (ICD) in tumor cells and co-administrate with checkpoint
inhibitors to improve the therapeutic efficacy. This study aims to investigate Oxaliplatin’s effect on a different gastric
carcinoma, SGC-7901, and analyze the therapeutic efficacy of its co-administration with the checkpoint inhibitor. To
evaluate the immunogenic cell death (ICD) induced by Oxaliplatin in SGC-7901, flow cytometry, HMGB1, ATP release,
and immunoblotting were conducted. The effectiveness of Oxaliplatin was analyzed using a vaccination approach and
subcutaneous tumor models to observe tumour regression. PD-L1 mRNA and protein levels in SGC-7901 were also
examined. The therapeutic efficacy of Oxaliplatin in murine lung tumor models will be enhanced by co-administering
with aPD-L1. Cisplatin will be employed as a positive control, while PBS will be a negative control. The result of the
study will provide important insight into the experimental effectiveness of Oxaliplatin in SGC-7901, it also sets the
basis for future experimental, preclinical, and clinical studies of the drug. Future studies should focus on practicing the
actual experiment on the experimental effectiveness of Oxaliplatin in SGC-7901 and look for the applicability of the
effectiveness of Oxaliplatin on other tumor cells.
References
[1] Siegel, Rebecca L., Kimberly D. Miller, and Ahmedin Jemal. “Cancer statistics, 2019.” CA: a cancer journal for clinicians 69.1 (2019): 7-34.
[2] Parkin, D. Maxwell. “Global cancer statistics in the year 2000.” The lancet oncology 2.9 (2001): 533-543.
[3] Sun, Fengfei, et al. “Oxaliplatin induces immunogenic cells death and enhances therapeutic efficacy of checkpoint inhibitor in a model of murine lung carcinoma.” journal of Receptors and Signal transduction 39.3 (2019): 208-214.
[4] Kroemer, Guido, et al. “Immunogenic cell death in cancer therapy.” Annual review of immunology 31 (2013): 51-72.
[5] Garg, Abhishek D., et al. “Immunogenic cell death.” International Journal of Developmental Biology 59.1-2-3 (2015): 131-140.
[6] Postow, Michael A., Margaret K. Callahan, and Jedd D. Wolchok. “Immune checkpoint blockade in cancer therapy.” Journal of clinical oncology 33.17 (2015): 1974.
[7] Misset, J. L. “Oxaliplatin in practice.” British journal of cancer 77.4 (1998): 4-7.
[8] Wang, Junqing, et al. “Suppressive effects on cell proliferation and motility in gastric cancer SGC-7901 cells by introducing ulinastatin in vitro.” Anti-Cancer Drugs 27.7 (2016): 651-659.
[9] Wu, Kun, Lin-Hong Yuan, and Wei Xia. “Inhibitory effects of apigenin on the growth of gastric carcinoma SGC-7901 cells.” World Journal of Gastroenterology: WJG 11.29 (2005): 4461.
[10] Wu, Ping, et al. “Oxaliplatin triggers necrosis as well as apoptosis in gastric cancer SGC-7901 cells.” Biochemical and biophysical research communications 460.2 (2015): 183-190.
[11] Li, Qi, et al. “P38 signal transduction pathway has more cofactors on apoptosis of SGC-7901 gastric cancer cells induced by combination of rutin and oxaliplatin.” BioMed Research International 2019 (2019).
Downloads
Published
Issue
Section
License
Copyright (c) 2023 by the authors.
This work is licensed under a Creative Commons Attribution 4.0 International License.
